Company Profile
Erasca Stock Price, News & Analysis
- Ticker:
- ERAS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.87 USD (-1.26%)
Close
Last updated: July 27, 2026
4.19B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ERAS closed down 1.26% at $18.87. No new same-company headline was identified in the current news window.
Company overview
Business overview
Erasca is an oncology company focused on precision medicine and targeted cancer therapies. Its pipeline is built to address genetically defined tumor biology.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Erasca sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical readouts, translational data, and the ability to create a differentiated oncology franchise.
Position Within the Biotechnology Landscape
Erasca is a small-cap oncology catalyst name whose stock can move quickly on early clinical data.
Future catalysts
The next few months for Erasca are centered on ERAS-0015 and RAS-targeted in ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in.... The latest company update points to Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class.... If that progress holds, the program should stay on the radar through the rest of the quarter.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Erasca (ERAS)?
Erasca (ERAS) most recently closed at 18.87 USD, a -1.26% move versus the previous session.
What is the market cap of Erasca (ERAS)?
Erasca currently has a market capitalization of 4.19B USD on BioPharmSignal.
What does Erasca do?
Erasca is an oncology company focused on precision medicine and targeted cancer therapies. Its pipeline is built to address genetically defined tumor biology.
On which exchange is ERAS stock listed?
Erasca (ERAS) is associated with NASDAQ, United States, Biopharma.
What is ERAS-0015?
The next few months for Erasca are centered on ERAS-0015 and RAS-targeted in ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in....
Which conditions is Erasca targeting with ERAS-0015?
Erasca is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Erasca describe recent progress with ERAS-0015?
The next few months for Erasca are centered on ERAS-0015 and RAS-targeted in ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in....
What is Erasca?
Erasca is an oncology company focused on precision medicine and targeted cancer therapies.